Nasdaq News

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which

Aimmune Therapeutics Inc (NASDAQ: AIMT) -- a California-based biotechnology company -- recently made history. The company's drug Palforzia became the first treatment for peanut allergies to be approved by the U.S. Food and Drug Administration (FDA). Naturally, investors received

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensiv

At Holdings Channel, we have reviewed the latest batch of the 31 most recent 13F filings for the 12/31/2019 reporting period, and noticed that Amazon.com Inc (Symbol: AMZN) was held by 18 of these funds. When hedge fund managers appear to be thinking alike, we find it is a goo

In trading on Monday, shares of Upland Software Inc (Symbol: UPLD) crossed above their 200 day moving average of $41.32, changing hands as high as $42.41 per share. Upland Software Inc shares are currently trading up about 3.8% on the day. The chart below shows the one year

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which

The Trump administration is floating a budget that will be released in full later today and, while it conforms to the modern reality, it looks like it will be more bad news for fiscal traditionalists.

In trading on Monday, shares of Alexander & Baldwin Inc (Symbol: ALEX) crossed above their 200 day moving average of $22.98, changing hands as high as $23.20 per share. Alexander & Baldwin Inc shares are currently trading up about 6.9% on the day. The chart below s

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the

In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view

Amazon Web Services said on Monday it was seeking to depose President Donald Trump and Defense Secretary Mark Esper in its lawsuit over whether the president was trying "to screw Amazon" when it awarded a Pentagon contract for cloud computing to rival Microsoft Corp.

(RTTNews) - After initially moving to the downside, stocks have shown a notable rebound over the course of morning trading on Monday. The major averages have bounced well off their lows of the session and into positive territory.

Dozens of climate activists invaded U.S. asset manager BlackRock's office in central Paris on Monday, calling for the fund to pull out of fossil fuel investments.

U.S. consumers' inflation expectations remained steady in January and workers became more optimistic about the job market, according to a Federal Reserve Bank of New York survey published on Monday.

Having genetically higher levels of the sex hormone testosterone increases the risk of developing diabetes and some types of cancer in women, and reduces diabetes risk but raises some cancer risks in men, according to research published on Monday.

(RTTNews) - Shares of clinical-stage biopharmaceutical company Kodiak Sciences Inc. (KOD) are climbing more than 6% on Monday followed by reporting additional safety, efficacy and durability data from the ongoing Phase 1b study of its investigational therapy KSI-301.